Erk1/2 phosphorylation has been shown to be unaltered or increased by enzastaurin in several cancer types [22], [24], [35]–[39], whereas Akt phosphorylation has been reported to be downregulated by enzastaurin, likely through an indirect mechanism as Akt is not a direct target of the drug [18], [24], [25]. Here, MAPK3 is linked to cancer.